Eylea approved in Japan for new CRVO indication
This article was originally published in Scrip
Executive Summary
Following a positive opinion in October, Japan has granted a formal final approval to Bayer's VEGF inhibitor Eylea (aflibercept) for the additional indication of macular edema secondary to central retinal vein occlusion (CRVO).